Black Box Trading Based on Algorithmic Trading: Returns up to 6.96% in 3 Days

Black Box Trading

This forecast is part of the Top 10 Stocks Package, as one of I Know First’s systematic trading tools. The full package includes a daily prediction for a total of 20 stocks with bullish and bearish signals:

  • Top 10 stocks pick for the long position
  • Top 10 stocks pick for the short position


Package Name: Top 10 Stocks
Recommended Positions: Long
Forecast Length: 3 Days (05/27/2018 – 05/30/2018)
I Know First Average: 2.01%
Black Box Trading

During the 3 Days forecasted period several picks in the Top 10 Stocks Package saw significant returns. The algorithm had correctly predicted 8 out 10 returns. The prediction with the highest return was FMI, at 6.96%. Further notable returns came from WSM and ALGN at 4.54% and 4.05%, respectively. The Top 10 Stocks package had an overall average return of 2.01%, providing investors with a premium of 1.91% over the S&P 500’s return of 0.10%.

Foundation Medicine, Inc., incorporated on November 12, 2009, is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company is engaged in the business of delivering molecular information about cancer to its customers. The Company’s platform includes various methods and algorithms for analyzing specimens across various types of cancer, and for incorporating that information into clinical care. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.